Info: Zenodo’s user support line is staffed on regular business days between Dec 23 and Jan 5. Response times may be slightly longer than normal.

Published December 22, 2022 | Version v1
Journal article Open

A Case Series Study to Assess the Clinical and Socio Demographic Aspects of MDR TB Clients Admitted in Selected Hospitals of Indore

  • 1. Rajdeep
  • 2. Madhurendra
  • 3. Kuldeep
  • 4. Shyam sundar

Description

The World Health Organization (WHO) defines multidrug-resistant tuberculosis (MDR-TB) as resistance to isoniazid and rifampicin, with or without

resistance to other anti-tuberculosis drugs. MDR-TB is a subtype of multidrug-resistant tuberculosis (MDR-TB). It is becoming a significant concern

for human health on a global basis, and it presents a threat to the efforts being made to control tuberculosis. According to the most recent statistics on

the monitoring of anti-TB drug resistance, it is estimated that 4.3% of newly diagnosed cases and 18% of previously treated cases of tuberculosis across

the globe have rifampicin- or multidrug-resistant tuberculosis. This percentage applies to cases that have been diagnosed with tuberculosis for the first

time (MDR- or RR-TB). According to estimates, there were around 700,000 newly diagnosed cases of MDR/RR-TB reported throughout the globe in

2018. In India, it is anticipated that each year there will be 1.4 lakh newly diagnosed cases of MDR-TB, with 80,000 of those cases being MDR-TB. In

the United States, the number of newly diagnosed cases of MDR-TB is estimated to reach 90,000.In light of the fact that the chest X-ray (CXR)

symptoms of pulmonary tuberculosis are dependent on a variety of characteristics, such as age and immunological status, identifying the influence of

HIV on the CXR appearances of MDR-TB may be of some help.

Multidrug-resistant tuberculosis (also known as MDR-TB) is a condition that is becoming an increasingly significant problem as a result of inadequate

treatment of drug-sensitive as well as drug-resistant tuberculosis. Both multidrug-resistant tuberculosis and regular tuberculosis may be cured; however,

treatment can be prohibitively expensive, take a very long time, and require treatments that might be potentially hazardous.

There have only been a few studies done that look at the clinical and demographic features of MDR-TB. Investigating the socio demographic aspects of

multidrug-resistant pulmonary tuberculosis is the goal of this study.

Files

IJRPR8779.pdf

Files (85.3 kB)

Name Size Download all
md5:8ceed505d39e686d9da0eb7244b1484d
85.3 kB Preview Download